Loxo Oncology, Inc. (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of Loxo Oncology stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $88.21, for a total value of $1,323,150.00. Following the completion of the transaction, the chief executive officer now directly owns 190,207 shares of the company’s stock, valued at $16,778,159.47. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Loxo Oncology, Inc. (LOXO) opened at $96.83 on Friday. The firm has a market capitalization of $3,100.00, a price-to-earnings ratio of -16.67 and a beta of 2.54. Loxo Oncology, Inc. has a fifty-two week low of $36.75 and a fifty-two week high of $98.00.
Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.38) by $0.26. equities research analysts predict that Loxo Oncology, Inc. will post -5.91 EPS for the current year.
Several equities analysts have weighed in on LOXO shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 price objective (up from $95.00) on shares of Loxo Oncology in a report on Friday, October 6th. Zacks Investment Research cut Loxo Oncology from a “hold” rating to a “sell” rating in a report on Friday, December 1st. William Blair started coverage on Loxo Oncology in a report on Tuesday, November 28th. They issued an “outperform” rating for the company. JMP Securities raised Loxo Oncology from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $77.18 to $95.00 in a report on Tuesday, November 14th. Finally, BidaskClub raised Loxo Oncology from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 12th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $90.57.
WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/21/loxo-oncology-inc-loxo-ceo-sells-1323150-00-in-stock.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.